SNN-0029

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSNN-0029
Drug Alias NamesNN 0029rhVEGF165 - Newron PharmaceuticalsTelbermin - Newron PharmaceuticalssNN-0029
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionNeurons stimulants
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlands
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNewron Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNewron Sweden Ab
Active IndicationsN/A
Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A